Peptide inhibitors of interleukin-23 receptor and uses thereof

Oral administration of a peptide inhibitor targeting IL-23R effectively treats GPP and EP, achieving substantial clinical improvements in psoriasis severity and quality of life measures.

WO2025151385A1 Publication Date: 2025-07-17JANSSEN PHARMA NV
2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/010515
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-05
Filing Date
2025-01-07
Publication Date
2025-07-17

AI Technical Summary

Technical Problem

There is an unmet need for oral therapies with high efficacy and a good safety profile for treating generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP), as current treatments are limited and there are no GPP-specific therapies approved in the USA or Europe.

Method used

A peptide inhibitor of the interleukin-23 receptor (IL-23R) or its pharmaceutically acceptable salts or solvates is administered orally in doses ranging from 100-300 mg per day to treat GPP and EP, with specific dosing regimens and fasting requirements to enhance efficacy.

Benefits of technology

The peptide inhibitor effectively achieves at least 'minimally improved' to 'very much improved' ratings in Clinical Global Impression (CGI) scale within 16-30 weeks, demonstrating significant improvement in psoriasis severity indices, body surface area involvement, and quality of life measures.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Uses of a peptide inhibitor of the interleukin-23 receptor (IL-23R) or a pharmaceutically acceptable salt or solvate form thereof for the treatment of generalized pustular psoriasis or erythrodermic psoriasis are described.
Need to check novelty before this filing date? Find Prior Art